S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle

AnaptysBio (ANAB) Stock Forecast, Price & News

$17.96
-0.04 (-0.22%)
(As of 09/29/2023 ET)
Compare
Today's Range
$17.43
$18.09
50-Day Range
$16.74
$20.56
52-Week Range
$16.51
$32.44
Volume
182,012 shs
Average Volume
291,710 shs
Market Capitalization
$476.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.75

AnaptysBio MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
93.5% Upside
$34.75 Price Target
Short Interest
Bearish
20.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.80mentions of AnaptysBio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$116,257 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.61) to ($6.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

872nd out of 972 stocks

Pharmaceutical Preparations Industry

411th out of 449 stocks


ANAB stock logo

About AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB Price History

ANAB Stock News Headlines

Argenx's 28% Surge & Promising Product Propel Investor Confidence (ANAB)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AnaptysBio (NASDAQ: ANAB)
JP Morgan Upgrades AnaptysBio (ANAB)
When Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven?
See More Headlines
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Company Calendar

Last Earnings
8/07/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANAB
Fax
N/A
Employees
96
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$34.75
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+93.5%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-128,720,000.00
Net Margins
-1,113.38%
Pretax Margin
-1,113.19%

Debt

Sales & Book Value

Annual Sales
$10.29 million
Book Value
$9.22 per share

Miscellaneous

Free Float
17,122,000
Market Cap
$476.84 million
Optionable
Optionable
Beta
-0.16

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Daniel R. Faga (Age 43)
    Pres, CEO & Director
    Comp: $867.12k
  • Mr. Eric J. LoumeauMr. Eric J. Loumeau (Age 60)
    Chief Legal Officer
    Comp: $685.59k
  • Dr. James N. Topper M.D. (Age 61)
    Ph.D., Advisor
    Comp: $86.5k
  • Mr. Hamza Suria M.B.A. (Age 47)
    M.Sc., Advisory
    Comp: $3.06M
  • Dr. Paul F. Lizzul FAAD (Age 48)
    M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer
    Comp: $656.36k
  • Mr. Dennis M. Mulroy (Age 68)
    Chief Financial Officer
  • Mr. Benjamin Stone
    Sr. VP of Corp. Devel.
  • Ms. Beth Mueller
    Sr. VP of HR
  • Dr. Martin Dahl Ph.D.
    Sr. VP of Research
  • Mr. Douglas A. Rich M.B.A (Age 54)
    M.B.A., Sr. VP of CMC













ANAB Stock - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings
or view top-rated stocks.

What is AnaptysBio's stock price forecast for 2023?

5 analysts have issued 1 year price objectives for AnaptysBio's shares. Their ANAB share price forecasts range from $26.00 to $45.00. On average, they anticipate the company's share price to reach $34.75 in the next twelve months. This suggests a possible upside of 93.5% from the stock's current price.
View analysts price targets for ANAB
or view top-rated stocks among Wall Street analysts.

How have ANAB shares performed in 2023?

AnaptysBio's stock was trading at $30.99 at the beginning of 2023. Since then, ANAB stock has decreased by 42.0% and is now trading at $17.96.
View the best growth stocks for 2023 here
.

When is AnaptysBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ANAB earnings forecast
.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. The biotechnology company earned $3.46 million during the quarter, compared to analyst estimates of $5.50 million. AnaptysBio had a negative net margin of 1,113.38% and a negative trailing twelve-month return on equity of 65.52%.

What ETF holds AnaptysBio's stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 5,859 shares of ANAB stock, representing 1.01% of its portfolio.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $17.96.

How much money does AnaptysBio make?

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $476.84 million and generates $10.29 million in revenue each year. The biotechnology company earns $-128,720,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.

This page (NASDAQ:ANAB) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -